Rationale COPD is an inflammatory lung disease largely associated with exposure to cigarette smoke (CS). The mechanism by which CS leads to the pathogenesis of COPD is currently unclear; it is known however that many of the inflammatory mediators present in the COPD lung can be produced via the actions of the transcription factor Nuclear Factor-kappaB (NF-κB) and its upstream signalling kinase, Inhibitor of κB kinase-2 (IKK-2). Therefore the NF-κB/IKK-2 signalling pathway may represent a therapeutic target to attenuate the inflammation associated with COPD. Aim To use a range of assays, genetically modified animals and pharmacological tools to determine the role of NF-κB in CS-induced airway inflammation. Methods NF-κB pathway activation was measured in pre-clinical models of CS-induced airway inflammation and in human lung tissue from COPD patients. This data was complemented by employing mice missing a functional NF-κB pathway in specific cell types (epithelial and myeloid cells) and with systemic inhibitors of IKK-2. Results We showed in an airway inflammation model known to be NF-κB-dependent that the NF-κB pathway activity assays and modulators were functional in the mouse lung. Then, using the same methods, we demonstrated that the NF-κB pathway appears not to play an important role in the inflammation observed after exposure to CS. Furthermore, assaying human lung tissue revealed that in the clinical samples there was also no increase in NF-κB pathway activation in the COPD lung, suggesting that our pre-clinical data is translational to human disease. Conclusions In this study we present compelling evidence that the IKK-2/NF-κB signalling pathway does not play a prominent role in the inflammatory response to CS exposure and that this pathway may not be important in COPD pathogenesis.
References
[1]
Barnes PJ (2007) Chronic Obstructive Pulmonary Disease: A Growing but Neglected Global Epidemic. PLoS Med. 4: 779–780.
[2]
World Health Organization (2008) World health statistics. Geneva. Available: http://www.who.int/whosis/whostat/2008/e？n/index.html.
[3]
Barnes PJ, Stockley RA (2005) COPD: Current therapeutic interventions and future approaches. Eur Respir J. 25: 1084–1106.
[4]
Di Stefano A, Turato G, Maestrelli P, Mapp CE, Ruggieri MP, et al. (1996) Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration in bronchial mucosa. Am J Respir Crit Care Med. 153: 629–632.
[5]
Saetta M, Turato G, Facchini FM, Corbino L, Lucchini RE, et al. (1997) Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med. 156: 1633–1639.
[6]
Hogg JC (2004) Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 364: 709–721.
[7]
Van der Strate BW, Postma DS, Brandsma CA, Melgert BN, Luinge MA (2006) Cigarette smoke-induced emphysema: A role for the B cell? Am J Respir Crit Care Med. 173: 751–758.
[8]
Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, et al. (2009) Targeting the NF-4444B pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther. 121: 1–13.
[9]
Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 336: 1066–1071.
[10]
Caramori G, Romagnoli P, Casolari P, Bellaettato, Casoni G, et al. (2003) Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax. 58: 348–351.
[11]
Di Stefano A, Caramori G, Oates T, Capelli A, Lusuardi M, et al. (2002) Increased expression of nuclear factor-κB in bronchial biopsies from smokers and patients with COPD. Eur Respir J. 20: 556–563.
[12]
Li Q, Van Antwerp D, Mercurio F, Lee K-F, Verma IM (1999) Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science 284: 321–325.
[13]
Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, et al. (2005) Attenuation of murine collagen-induced arthritis by a novel, potent and selective small molecule inhibitor of IκB kinase 2, TPCA-1, occurs via reduction of pro-inflammatory cytokines and antigen-induced T cell proliferation. J Pharmacol Exp Ther 312: 373–381.
[14]
Birrell MA, Hardaker E, Wong S, McCluskie K, Catley M, et al. (2005) Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am J Respir Crit Care Med. 172: 962–971.
[15]
Murata T, Shimada M, Sakakibara S, Yoshino T, Masuda T, et al. (2004) Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents. Bioorg Med Chem Lett. 14: 4019–4022.
[16]
Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F (1999) Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 274: 10689–10692.
[17]
Birrell MA, Wong S, Hardaker EL, Catley MC, McCluskie K, et al. (2006) IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol. 69: 1791–1800.
[18]
Perl AK, Wert SE, Nagy A, Lobe CG, Whitsett JA (2002) Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc Natl Acad Sci U S A. 99: 10482–10487.
[19]
Clausen BE, Burkhardt C, Reith W, Renkawitz R, F？rster I (1999) Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8: 265–277.
[20]
Perl AK, Wert SE, Loudy DE, Shan Z, Blair PA, et al. (2005) Conditional recombination reveals distinct subsets of epithelial cells in trachea, bronchi, and alveoli. Am J Respir Cell Mol Biol. 33: 455–462.
[21]
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 118: 285–296.
[22]
Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M (2010) Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell. 17: 89–97.
[23]
Eltom S, Stevenson CS, Rastrick J, Dale N, Raemdonck K, et al. (2011) P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. PLoS One. 6: e24097.
[24]
Yang SR, Valvo S, Yao H, Kode A, Rajendrasozhan S, et al. (2008) IKK alpha causes chromatin modification on pro-inflammatory genes by cigarette smoke in mouse lung. Am J Respir Cell Mol Biol. 38: 689–698.
[25]
Yao H, Edirisinghe I, Rajendrasozhan S, Yang SR, Caito S, et al. (2008) Cigarette smoke-mediated inflammatory and oxidative responses are strain-dependent in mice. Am J Physiol Lung Cell Mol Physiol. 294: L1174–1186.
[26]
Valenca SS, Castro P, Pimenta WA, Lanzetti M, Silva SV, et al. (2006) Light cigarette smoke-induced emphysema and NFkappaB activation in mouse lung. Int J Exp Pathol. 87: 373–381.
[27]
Vlahos R, Bozinovski S, Jones JE, Powell J, Gras J, et al. (2006) Differential protease, innate immunity, and NF-kappaB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice. Am J Physiol Lung Cell Mol Physiol. 290: L931–945.
[28]
Thatcher TH, Maggirwar SB, Baglole CJ, Lakatos HF, Gasiewicz TA, et al. (2007) Aryl hydrocarbon receptor-deficient mice develop heightened inflammatory responses to cigarette smoke and endotoxin associated with rapid loss of the nuclear factor-kappaB component RelB. Am J Pathol. 170: 855–864.
[29]
Li YT, He B, Wang YZ, Wang J (2009) Effects of intratracheal administration of nuclear factor-kappaB decoy oligodeoxynucleotides on long-term cigarette smoke-induced lung inflammation and pathology in mice. Respir Res. 10: 79.
[30]
Rajendrasozhan S, Hwang JW, Yao H, Kishore N, Rahman I (2010) Anti-inflammatory effect of a selective IkappaB kinase-beta inhibitor in rat lung in response to LPS and cigarette smoke. Pulm Pharmacol Ther. 23: 172–181.
[31]
Marwick JA, Kirkham PA, Stevenson CS, Danahay H, Giddings J, et al. (2004) Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mol Biol. 31: 633–642.
[32]
Lixuan Z, Jingcheng D, Wenqin Y, Jianhua H, Baojun L, et al. (2010) Baicalin attenuates inflammation by inhibiting NF-kappaB activation in cigarette smoke induced inflammatory models. Pulm Pharmacol Ther. 23: 411–419.
[33]
Rajendrasozhan S, Chung S, Sundar IK, Yao H, Rahman I (2010) P50 Targeted disruption of NF-{kappa}B1 (p50) augments cigarette smoke-induced lung inflammation and emphysema in mice: a critical role of p50 in chromatin remodeling. Am J Physiol Lung Cell Mol Physiol. 298: L197–209.
[34]
Li YT, He B, Wang YZ, Wang J (2009) Effects of intratracheal administration of nuclear factor-kappaB decoy oligodeoxynucleotides on long-term cigarette smoke-induced lung inflammation and pathology in mice. Respir Res. 10: 79.
[35]
Tharappel JC, Cholewa J, Espandiari P, Spear BT, Gairola CG, et al. (2010) Effects of cigarette smoke on the activation of oxidative stress-related transcription factors in female A/J mouse lung. J Toxicol Environ Health A. 73: 1288–1297.
[36]
Gottipati KR, Poulsen H, Starcher B (2008) Passive cigarette smoke exposure inhibits ultraviolet light B-induced skin tumors in SKH-1 hairless mice by blocking the nuclear factor kappa B signalling pathway. Exp Dermatol. 17: 780–787.
[37]
Zhong CY, Zhou YM, Pinkerton KE (2008) NF-kappaB inhibition is involved in tobacco smoke-induced apoptosis in the lungs of rats. Toxicol Appl Pharmacol. 230: 150–158.
[38]
Zhong CY, Zhou YM, Joad JP, Pinkerton KE (2006) Environmental tobacco smoke suppresses nuclear factor-kappaB signaling to increase apoptosis in infant monkey lungs. Am J Respir Crit Care Med. 174: 428–436.
[39]
Szulakowski P, Crowther AJL, Luis A, Jimenez LA, Donaldson K, et al. (2006) The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 174: 41–50.
[40]
Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, et al. (2004) Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax. 60: 293–300.
[41]
Beg AA, Baltimore D (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274: 782–784.
[42]
Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, et al. (2007) NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell. 130: 918–931.
[43]
Fong CH, Bebien M, Didierlaurent A, Nebauer R, Hussell T, et al. (2008) An antiinflammatory role for IKKbeta through the inhibition of “classical” macrophage activation. J Exp Med. 205: 1269–1276.
[44]
Tudhope SJ, Catley MC, Fenwick PS, Russell RE, Rumsey WL, et al. (2007) The role of IkappaB kinase 2, but not activation of NF-kappaB, in the release of CXCR3 ligands from IFN-gamma-stimulated human bronchial epithelial cells. J Immunol. 179(9): 6237–45.
[45]
Jacque E, Tchenio T, Piton G, Romeo PH, Baud V (2005) RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. PNAS. 102(41): 14635–14640.
[46]
Lee SY, Miller M, Cho JY, Song DJ, et al. (2010) Inactivation of I kappaB-kinase-beta dependent genes in airway epithelium reduces tobacco smoke induced acute airway inflammation. Int Immunopharmacol. 10: 906–912.
[47]
Oliver KM, Garvey JF, Ng CT, Veale DJ, Fearon U, et al. (2009) Hypoxia activates NF-kappaB-dependent gene expression through the canonical signaling pathway. Antioxid Redox Signal. 11: 2057–2064.
[48]
Broide DH, Lawrence T, Doherty T, Cho JY, Miller M, et al. (2005) Allergen-induced peribronchial fibrosis and mucus production mediated by IkappaB kinase beta-dependent genes in airway epithelium. Proc Natl Acad Sci U S A. 102: 17723–17728.
[49]
Culpitt SV, Nightingale JA, Barnes PJ (1999) Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 160: 1635–1639.
[50]
Keatings VM, Jatakanon A, Worsdall YM, Barnes PJ (1997) Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 155: 542–548.
